You just read:

Merck Announces Initial Results for Pembrolizumab with Novel Immunotherapy Combinations from Three Investigational Studies Presented at the Society for Melanoma Research International Congress

News provided by

Merck Canada Inc.

Nov 21, 2015, 16:59 ET